Αποτελέσματα Αναζήτησης
1 ημέρα πριν · Contacts. Media Contacts: Felicia Bisaro (646) 703-1807 Kim Hamilton (908) 391-0131 Investor Contacts: Jennifer Halchak (201) 275-2711
1 ημέρα πριν · Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
23 Οκτ 2024 · The latest CDC numbers show least 90 cases of E. coli reported in 13 states, up from 49 reported in 10 states on Oct. 22, but "the true number of sick people is likely much higher," the CDC said.
1 Οκτ 2024 · The list below provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products.
29 Οκτ 2024 · Dr. Elder: Yes. A class I recall is the most serious, where there is a reasonable probability that using or being exposed to the recalled drug will cause serious adverse health consequences for a ...
Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin [1] that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.
Exanta FDA Approval Status. FDA Approved: No. Brand name: Exanta. Generic name: ximelagatran. Company: AstraZeneca. Treatment for: Prevention of Thromboembolism in Atrial Fibrillation. Exanta (ximelagatran) is an investigational oral direct thrombin inhibitor (oral DTI) intended for use in the prevention of strokes in patients with atrial ...
